Nodularin‐R Synergistically Enhances Abiraterone Against Castrate‐ Resistant Prostate Cancer via PPP1CA Inhibition
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.70210 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Yiqiao Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Androstenes, Drug Resistance, Neoplasm, Protein Phosphatase 1. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangzhou Core Medical Disciplines Project (2021-2023), Guangzhou Municipal Science and Technology Bureau Municipal Finance - Supporting Institution Jointly funded project Funds, National Natural Science Foundation of China.
Abstract (Originalsprache)
Clinically, most prostate cancer (PCa) patients inevitably progress to castration‐resistant prostate cancer (CRPC) with poor prognosis after androgen deprivation therapy (ADT), including abiraterone, the drug of choice for ADT. Therefore, it is necessary to explore the resistance mechanism of abiraterone in depth. Genome‐wide CRISPR/Cas9 knockout technology was used to screen CRPC cell line 22Rv1 for abiraterone‐resistant genes. Combined with bioinformatics, a key gene with high expression and poor prognosis in CRPC patients was screened. Then, the effects of target gene on abiraterone‐resistant 22Rv1 cell function were explored by silencing and overexpression. Further, a natural product with potential targeting effect was identified and validated by molecular docking and protein expression. Molecular dynamics simulations revealed potential mechanism for the natural product affecting target protein expression. Finally, the combined anti‐CRPC effects of the natural product and abiraterone were validated by cellular and in vivo experiments. Five common resistance genes (KCNJ3, COL2A1, PPP1CA, MDH2 and EXOSC5) were identified successfully, among which high PPP1CA expression had the worst prognosis for disease‐free survival. Moreover, PPP1CA was highly expressed in abiraterone‐resistant 22Rv1 cells. Silencing PPP1CA increased cell sensitivity to abiraterone while promoting apoptosis and inhibiting clone formation. Overexpressing PPP1CA exerted the opposite effects. Molecular docking revealed the binding mode of the natural product nodularin‐R to PPP1CA with a dose‐dependent manner for inhibition. Mechanistically, nodularin‐R attenuates the interaction between PPP1CA and USP11 (deubiquitinating enzyme), potentially promoting PPP1CA degradation. Additionally, combination of 2.72 μM nodularin‐R and 54.5 μM abiraterone synergistically inhibited the resistant 22Rv1 cell function. In vivo experiments also revealed that combination therapy significantly inhibited tumour growth and reduced inducible expression of PPP1CA. PPP1CA is a key driver for abiraterone resistance, and nodularin‐R enhances the anti‐CRPC effects of abiraterone by inhibiting PPP1CA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Urology, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Chi…
- Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.
- Department of Gynecology, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou,…
- School of Life Sciences, Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Zhengming Su, Anyang Wei
Förderung
- Guangzhou Core Medical Disciplines Project (2021-2023)
- Guangzhou Municipal Science and Technology Bureau Municipal Finance - Supporting Institution Jointly funded project Funds
- National Natural Science Foundation of China
- Project of Medical Scientific Research in Guangdong
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Huang, Y., Cen, Y., Wu, H., Zeng, G., Su, Z., Zhang, Z., Feng, S., Jiang, X., & Wei, A. (2024). Nodularin‐R Synergistically Enhances Abiraterone Against Castrate‐ Resistant Prostate Cancer via PPP1CA Inhibition. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70210
Vancouver
Huang Y, Cen Y, Wu H, Zeng G, Su Z, Zhang Z, et al. Nodularin‐R Synergistically Enhances Abiraterone Against Castrate‐ Resistant Prostate Cancer via PPP1CA Inhibition. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70210
BibTeX
@article{Huang2024,
author = {Huang, Yiqiao and Cen, Yi and Wu, Hualing and Zeng, Guohao and Su, Zhengming and Zhang, Zhiming and Feng, Shourui and Jiang, Xianhan and Wei, Anyang},
title = {Nodularin‐R Synergistically Enhances Abiraterone Against Castrate‐ Resistant Prostate Cancer via PPP1CA Inhibition},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.70210}
}
EUVIMED